Endo To Receive Milestone Payment On First Sale Of XIAFLEX In Japan

(RTTNews) - Endo International plc (ENDP, ENL.TO) announced that XIAFLEX for the treatment of Dupuytren's contracture has been listed on the Japanese National Health Insurance drug price standard. As a result, Endo partner Asahi Kasei Pharma expects to commercially launch the product in Japan on September 16, 2015. Endo will receive a $20 million milestone payment upon the first commercial sale of XIAFLEX in Japan.

Dupuytren's contracture is a progressive condition affecting the hand, specifically the layer of tissue just under the skin of the palm and fingers. XIAFLEX is a biologic approved in the U.S., EU, Canada, Australia and Japan for the treatment of adult Dupuytren's contracture patients. Asahi Kasei Pharma obtained approval in Japan for the manufacture and marketing of XIAFLEX for Dupuytren's contracture in July 2015.

Endo said it is eligible to receive up to $217 million in remaining potential milestone payments and up to $210 million in connection with the achievement of aggregate annual net sales thresholds. Asahi Kasei Pharma will provide tiered payments based on net sales of XIAFLEX.